Wave Life Sciences linked its obesity drug candidate to a 1% dip in body weight after six months, leading investors to drive ...

Innate Pharma has finally called time on a NK cell engager in phase 1/2 development as part of an ongoing fine-tuning of the French biotech’s pipeline. | Innate Pharma has finally called time on a NK ...

Following an FDA green light last December for its upgraded robot, CMR Surgical has begun rolling out its Versius Plus ...

Oral peptide specialist Pinnacle Medicines has secured an $89 million series B with backing from investors in the U.S. and ...

Philips has secured an FDA clearance for its artificial intelligence program that tracks and guides the placement of a ...

Biopharma funding fell 20% last year, reversing the post-pandemic recovery as the IPO haul dropped to the lowest level of the ...

Pulmatrix may have been discarded by Cullgen, but the inhaled therapy biotech’s Nasdaq listing has caught the attention of ...

Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the ...

China’s BrightGene has served up a slice of early-stage data to remind everyone it has a horse in the oral obesity race.  | ...

Sarepta Therapeutics has shared initial clinical data on two siRNA candidates, delivering an early look at the wisdom of its ...

Endogenex has raised $50 million in venture capital financing to complete the development of its minimally invasive procedure ...

Innovent Biologics’ eye disease prospect has matched Bayer and Regeneron’s Eylea in a phase 3 study, teeing up filings for ...